Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06BKH
|
|||
| Former ID |
DIB009472
|
|||
| Drug Name |
GR-MD-02
|
|||
| Synonyms |
Belapectin
Click to Show/Hide
|
|||
| Drug Type |
Protein
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 2 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [2], [3], [4] | ||
| Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 2 | [5], [4] | ||
| Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 1 | [6] | ||
| Company |
Galectin therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Galectin-3 (LGALS3) | Target Info | Inhibitor | [7] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | Hedgehog signaling events mediated by Gli proteins | |||
| Regulation of Ras family activation | ||||
| Reactome | Advanced glycosylation endproduct receptor signaling | |||
| WikiPathways | Spinal Cord Injury | |||
| AGE/RAGE pathway | ||||
| Advanced glycosylation endproduct receptor signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02462967) Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 6 | ClinicalTrials.gov (NCT01899859) Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. U.S. National Institutes of Health. | |||
| REF 7 | Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.